Cover Image
市場調查報告書

大腸菌感染疾病:開發中產品分析

Escherichia coli Infections - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 253652
出版日期 內容資訊 英文 165 Pages
訂單完成後即時交付
價格
Back to Top
大腸菌感染疾病:開發中產品分析 Escherichia coli Infections - Pipeline Review, H2 2016
出版日期: 2016年11月23日 內容資訊: 英文 165 Pages
簡介

大腸菌一般存在於健康的人類及動物的腸內。大腸菌感染是接觸了人或動物的糞便、或是攝取被糞便污染的食物或水而引起的。症狀有下痢(由輕度的水便到重度的出血)、腸部痙攣、腹痛·腹部壓痛、噁心和嘔吐等。致病要素有年齡、免疫力降低、某種特定食物(未充分加熱的漢堡、未低溫殺菌的牛奶、蘋果汁·汽水、生乳做成的奶油奶酪等)。治療方法包含了抗生素、健康的生活習慣等。

本報告提供大腸菌感染疾病的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

大腸菌感染疾病概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • Adenium Biotech ApS
  • Arsanis Biosciences GmbH
  • AstraZeneca Plc
  • AvidBiotics Corp.
  • Bioorganic Research and Services S.A.
  • Cellceutix Corporation
  • Cytovation AS
  • Debiopharm International SA
  • Emergent BioSolutions Inc.
  • F. Hoffmann-La Roche Ltd.
  • GangaGen Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Melinta Therapeutics, Inc
  • Microbiotix, Inc.
  • MicuRx Pharmaceuticals, Inc.
  • Nabriva Therapeutics AG
  • Navigen Pharmaceuticals, Inc.
  • Nosopharm SAS
  • Novabiotics Limited
  • Omnia Molecular Ltd.
  • Pherecydes Pharma SA
  • Phico Therapeutics Limited
  • Procarta Biosystems Limited
  • Sealife PHARMA GMBH
  • Soligenix, Inc.
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc.
  • Varinel, Inc.
  • Visterra, Inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8693IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections - Pipeline Review, H2 2016, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape.

Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into contact with the feces, or stool, of humans or animals or drink water or eat food that has been contaminated by feces. Symptoms include diarrhea, which may range from mild and watery to severe and bloody, abdominal cramping, pain or tenderness, nausea and vomiting. The predisposing factors include age, weakened immune systems and eating certain types of food like undercooked hamburger, unpasteurized milk, apple juice or cider and soft cheeses made from raw milk. Treatment includes antibiotics and healthy life style.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Escherichia coli Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Escherichia coli Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Escherichia coli Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 31 and 24 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 14 molecules, respectively.Escherichia coli Infections.

Escherichia coli Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Escherichia coli Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Escherichia coli Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Escherichia coli Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Escherichia coli Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Escherichia coli Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Escherichia coli Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Escherichia coli Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Escherichia coli Infections Overview
  • Therapeutics Development
  • Pipeline Products for Escherichia coli Infections - Overview
  • Pipeline Products for Escherichia coli Infections - Comparative Analysis
  • Escherichia coli Infections - Therapeutics under Development by Companies
  • Escherichia coli Infections - Therapeutics under Investigation by Universities/Institutes
  • Escherichia coli Infections - Pipeline Products Glance
  • Clinical Stage Products
  • Early Stage Products
  • Escherichia coli Infections - Products under Development by Companies
  • Escherichia coli Infections - Products under Investigation by Universities/Institutes
  • Escherichia coli Infections - Companies Involved in Therapeutics Development
  • Adenium Biotech ApS
  • Arsanis, Inc.
  • AstraZeneca Plc
  • AvidBiotics Corp
  • Cellceutix Corp
  • Debiopharm International SA
  • Emergent BioSolutions Inc
  • F. Hoffmann-La Roche Ltd
  • GangaGen Inc
  • Hsiri Therapeutics LLC
  • Johnson & Johnson
  • Melinta Therapeutics Inc
  • Merck & Co Inc
  • Microbiotix Inc
  • Nabriva Therapeutics AG
  • Navigen Pharmaceuticals, Inc.
  • Nosopharm SAS
  • Novabiotics Ltd
  • Omnia Molecular Ltd
  • Paratek Pharmaceuticals Inc
  • Pherecydes Pharma SA
  • Phico Therapeutics Ltd
  • Procarta Biosystems Limited
  • Sealife PHARMA GMBH
  • Sequoia Sciences Inc
  • Soligenix Inc
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc
  • Varinel Inc
  • Escherichia coli Infections - Therapeutics Assessment
  • Assessment by Monotherapy Products
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Drug Profiles
  • A-3APO - Drug Profile
  • AA-139 - Drug Profile
  • AM-8722 - Drug Profile
  • ASN-4 - Drug Profile
  • AvR2-V10 - Drug Profile
  • BC-7634 - Drug Profile
  • BC-9074 - Drug Profile
  • BC-9529 - Drug Profile
  • BC-9563 - Drug Profile
  • BIZ-20131 - Drug Profile
  • BIZ-20132 - Drug Profile
  • BIZ-20133 - Drug Profile
  • CA-824 - Drug Profile
  • CC-1807 - Drug Profile
  • Debio-1454 - Drug Profile
  • Drugs for Bacterial Infections - Drug Profile
  • dusquetide - Drug Profile
  • Escherichia coli (whole cell) vaccine - Drug Profile
  • Escherichia coli vaccine - Drug Profile
  • Escherichia coli vaccine - Drug Profile
  • ETEC [strain B7A] vaccine - Drug Profile
  • ETEC vaccine - Drug Profile
  • EV-035 - Drug Profile
  • GN-4474 - Drug Profile
  • GNEG SNARE - Drug Profile
  • HT-07 - Drug Profile
  • INX-201 - Drug Profile
  • JNJ-63871860 - Drug Profile
  • MBX-2319 - Drug Profile
  • MDN-0057 - Drug Profile
  • mirandamycin - Drug Profile
  • NBTI-5463 - Drug Profile
  • NOSO-95179 - Drug Profile
  • NP-432 - Drug Profile
  • omadacycline tosylate - Drug Profile
  • Onc-72 - Drug Profile
  • P-100031 - Drug Profile
  • Peptides for Infectious Diseases - Drug Profile
  • PMX-100 - Drug Profile
  • PMX-1091 - Drug Profile
  • PMX-1142 - Drug Profile
  • PMX-1241 - Drug Profile
  • PMX-1278 - Drug Profile
  • PMX-1363 - Drug Profile
  • PMX-1405 - Drug Profile
  • PMX-223 - Drug Profile
  • PMX-229 - Drug Profile
  • PMX-247 - Drug Profile
  • PMX-633 - Drug Profile
  • PMX-668 - Drug Profile
  • PMX-693 - Drug Profile
  • PMX-843 - Drug Profile
  • PP-0121 - Drug Profile
  • Proteins for Infectious Diseases - Drug Profile
  • PT-5 - Drug Profile
  • Recombinant Protein for Escherichia Coli Infections - Drug Profile
  • RX-05 - Drug Profile
  • RXP-873 - Drug Profile
  • SE-1 - Drug Profile
  • Shigetec - Drug Profile
  • SLP-0901 - Drug Profile
  • SLP-0905 - Drug Profile
  • Small Molecule for Malaria and Bacterial Infections - Drug Profile
  • Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile
  • Small Molecules for Bacterial Infections and Lung Infection - Drug Profile
  • Small Molecules for Escherichia Coli Infections - Drug Profile
  • Small Molecules for Escherichia coli Infections - Drug Profile
  • Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile
  • Small Molecules to Inhibit 16S rRNA, Topoisomerases II and IV for Bacterial Infections - Drug Profile
  • Small Molecules to Inhibit Aminoacyl-tRNA Synthetases for Bacterial Infections - Drug Profile
  • Small Molecules to Inhibit RecA for Bacterial Infections - Drug Profile
  • SPR-741 - Drug Profile
  • Synthetic Peptide for Gram-Negative Bacterial Infections - Drug Profile
  • Synthetic Peptide for Oncology and Infectious Disease - Drug Profile
  • Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile
  • Synthetic Peptide to Target Bacterial Cell Membrane for Gram Negative and Gram Positive Bacterial Infections - Drug Profile
  • Synthetic Peptides for Escherichia Coli Infections - Drug Profile
  • TP-6076 - Drug Profile
  • VAR-10100 - Drug Profile
  • Escherichia coli Infections - Dormant Projects
  • Escherichia coli Infections - Discontinued Products
  • Escherichia coli Infections - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Escherichia coli Infections, H2 2016
  • Number of Products under Development for Escherichia coli Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Escherichia coli Infections - Pipeline by Adenium Biotech ApS, H2 2016
  • Escherichia coli Infections - Pipeline by Arsanis, Inc., H2 2016
  • Escherichia coli Infections - Pipeline by AstraZeneca Plc, H2 2016
  • Escherichia coli Infections - Pipeline by AvidBiotics Corp, H2 2016
  • Escherichia coli Infections - Pipeline by Cellceutix Corp, H2 2016
  • Escherichia coli Infections - Pipeline by Debiopharm International SA, H2 2016
  • Escherichia coli Infections - Pipeline by Emergent BioSolutions Inc, H2 2016
  • Escherichia coli Infections - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
  • Escherichia coli Infections - Pipeline by GangaGen Inc, H2 2016
  • Escherichia coli Infections - Pipeline by Hsiri Therapeutics LLC, H2 2016
  • Escherichia coli Infections - Pipeline by Johnson & Johnson, H2 2016
  • Escherichia coli Infections - Pipeline by Melinta Therapeutics Inc, H2 2016
  • Escherichia coli Infections - Pipeline by Merck & Co Inc, H2 2016
  • Escherichia coli Infections - Pipeline by Microbiotix Inc, H2 2016
  • Escherichia coli Infections - Pipeline by Nabriva Therapeutics AG, H2 2016
  • Escherichia coli Infections - Pipeline by Navigen Pharmaceuticals, Inc., H2 2016
  • Escherichia coli Infections - Pipeline by Nosopharm SAS, H2 2016
  • Escherichia coli Infections - Pipeline by Novabiotics Ltd, H2 2016
  • Escherichia coli Infections - Pipeline by Omnia Molecular Ltd, H2 2016
  • Escherichia coli Infections - Pipeline by Paratek Pharmaceuticals Inc, H2 2016
  • Escherichia coli Infections - Pipeline by Pherecydes Pharma SA, H2 2016
  • Escherichia coli Infections - Pipeline by Phico Therapeutics Ltd, H2 2016
  • Escherichia coli Infections - Pipeline by Procarta Biosystems Limited, H2 2016
  • Escherichia coli Infections - Pipeline by Sealife PHARMA GMBH, H2 2016
  • Escherichia coli Infections - Pipeline by Sequoia Sciences Inc, H2 2016
  • Escherichia coli Infections - Pipeline by Soligenix Inc, H2 2016
  • Escherichia coli Infections - Pipeline by Syntiron LLC, H2 2016
  • Escherichia coli Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2016
  • Escherichia coli Infections - Pipeline by Varinel Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Escherichia coli Infections - Dormant Projects, H2 2016
  • Escherichia coli Infections - Dormant Projects (Contd..1), H2 2016
  • Escherichia coli Infections - Dormant Projects (Contd..2), H2 2016
  • Escherichia coli Infections - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Escherichia coli Infections, H2 2016
  • Number of Products under Development for Escherichia coli Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top